🚩 On the watch list, its certificate can't be verified in its own name.
Neoviapeptides shows a genuine Janoshik report to look legitimate, but the client named on that certificate is liyudaily.com (a Chinese factory), not Neoviapeptides. In other words it has never paid to test its own stock; it has taken a certificate that proves a sample from its supplier's own line, and presents it as proof of what's in the vial it ships. The buyer is shown real-looking science that is, for their purposes, meaningless, there is no link between that certificate and the product they receive.
The certificate, and what's wrong with it
What this certificate actually is: Read the client / manufacturer field: it names a different company, a supplier, not this seller. The test is borrowed; it proves a supplier's batch, not this shop's stock.
⏳ This certificate is dated Sep 2025, 10 months old. A Certificate of Analysis only covers the single batch that was tested. Unless the seller has re-tested since, the stock you'd receive today is unverified, or it has sold the same batch for 10 months, which for a peptide is not credible.
Pricing vs the market, benchmarked on BPC-157
BPC-157
£2.9/mg (≈ £29 for a 10 mg vial)
Versus market median (£3.0/mg)
0.97×, competitive
In line with the wider UK market. The Peptide Watch benchmarks every vendor on the same compound, BPC-157, the most common research peptide, as £ per milligram, so prices are directly comparable across all providers.
The audit checklist
Check
Result
Verifiable certificate in its own name
No
Independent lab named
Janoshik, but borrowed
Tests its own stock
No evidence
Pricing vs market
0.97× median (competitive)
The bottom line. Neoviapeptides sits on the watch list because it does not publish a certificate that can be verified in its own name. Everything above is observable on its own website and the public record. See the vendors whose certificates are actually their own →
⚠️ Is anything on this page wrong or out of date? Submit a correction request and we'll look into it, vendors welcome too.